Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep
Varegacestat, a gamma secretase inhibitor, significantly improved progression-free survival while also meeting all key secondary endpoints in the pivotal RINGSIDE trial. Immunome is planning an FDA application for the second quarter of 2026.
Immunome Heads to the FDA With Desmoid Tumor Drug After Phase III Sweep Read More »
